The US Compounding Pharmacies Market size is forecast to grow at a CAGR of 8.88% from 2025 to 2034. The market is expected to reach USD 13,808.0 Million by 2034, up from USD 6,363.6 Million in 2025.
Overview
Research Analyst of BRI, with a background of expertise in industry trends. Various factors such as rapidly aging population, presence of well-developed healthcare infrastructure, increasing investment in the Compounding Pharmacies, increasing awareness of healthcare, rising demand for personalized medicines and growing technological innovations.
Growth Factors and Dynamics
- Rising Aging Population: The increasing aging population across the U.S. due to changing demographic structure is expected to create the demand for compoundable pharmacies during the forecast period. The growing number of older people is a big reason why the compounding pharmacy market is growing. This is because older people often need medicines that are tailored to their needs, which standard pharmaceutical manufacturing can’t provide. Older people often take more than one medicine, which makes it necessary to make custom formulations that make it easier to take pills. Older adults may not be able to handle standard drug strengths because their metabolism is slower and they are more sensitive.
- Rapidly expanding healthcare access and insurance coverage: The growing healthcare access and increasing insurance coverage coupled with the growing affordability of Compounding Pharmacies due to increasing insurance coverage are expected to create lucrative opportunities for the market during the forecast period. Together, these drivers are expected to sustain steady growth in the U.S. market, which is projected to continue at a moderate CAGR through 2030.
- Personalized medicine is gaining strong acceptance in the U.S.: The FDA and other regulatory bodies are giving the green light to advanced diagnostics, and there is a growing need for personalized therapies that work better and have fewer side effects. The FDA approved 18 new personalized medicines and six gene/cell-based therapies in 2024 alone. This shows how common personalized medicine is becoming in healthcare. The FDA’s proactive stance, which includes approving new therapies and diagnostic systems, shows that institutions support personalized medicine.
Report Scope
| Feature of the Report | Details |
| Market Size in 2025 | USD 6,363.6 Million |
| Projected Market Size in 2034 | USD 13,808.0 Million |
| Market Size in 2024 | USD 5,898.23 Million |
| CAGR Growth Rate | 8.88% CAGR |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Key Segment | By Type, Therapeutic Area, Age, Compounding Type, Sterility Type and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
SWOT Analysis
- Strengths: The U.S. compounding pharmacies market is good because it can make medicines that are just right for each patient. This includes changing the doses, getting rid of allergens, and finding new ways to give the medicine, such as liquids or creams. Compounding pharmacies fill in important gaps left by mass-produced drugs. This is important because more people are getting older and more people are getting chronic conditions. This makes patients trust and stay with you.
- Weakness: Compounding pharmacies have some good points, but they also have some big problems because there are no universal rules and regulations about how to use them. The FDA’s regulatory scrutiny is still a problem because compounded drugs don’t have official approval. Operations take a lot of work, which makes them more expensive and less scalable than those of big drug companies. Patients may not feel as confident if there are problems with quality assurance between providers. Also, reimbursement limits make it harder for patients who need personalized therapies to get them.
- Opportunities: There are many chances as more and more people get chronic diseases and personalized medicine becomes more popular. Compounding pharmacies can become experts in certain areas, such as pediatrics, veterinary care, and hormone replacement therapy. Automation and AI are two new technologies that will probably make compounding easier. When you add in trends in precision medicine in oncology, dermatology, and endocrinology, their strategic role in U.S. healthcare gets even stronger.
- Threats: More competition from big drug companies that are entering the personalization market could hurt market share. It is harder for patients to pay for care when insurance doesn’t pay for it, and contamination or bad formulations can get you in trouble with the law. When bigger companies buy up smaller ones, the market could become less diverse and less innovative. To keep growth going and patients’ trust in compounded therapies, you have to be very careful about how you deal with these outside pressures.
List of the prominent players in the US Compounding Pharmacies Market:
- Avella Specialty Pharmacy
- Central Admixture Pharmacy Services Inc.
- Clinigen Limited
- Fagron
- Fresenius Kabi USA
- ImprimisRx (Harrow Health Inc.)
- PenCol Pharmacy
- Sixth Avenue Medical Pharmacy
- Triangle Compounding
- Vertisis Custom Pharmacy
- Others
The US Compounding Pharmacies Market is segmented as follows:
By Type
- 503A
- 503B
By Therapeutic Area
- Hormone replacement therapy
- Pain management
- Specialty drugs
- Dermatolog
- Nutritional Supplements
- Others
By Age
- Pediatric
- Adult
- Geriatric
By Compounding Type
- Pharmaceutical Ingredient Alteration (PIA)
- Currently Unavailable Pharmaceutical Manufacturing (CUPM)
- Pharmaceutical Dosage Alteration (PDA)
- Others
By Sterility Type
- Sterile
- Non sterile
[embedsocial_reviews id=”d4ae80cffae3d938f997111953699a733c8e6f99″]